MoCadb-logoMoCadb - Study ID Exp24526730c

PubMed ID24526730
AuthorsQiu Y(1), Cai G, Zhou B, Li D, Zhao A, Xie G, Li H, Cai S, Xie D, Huang C, Ge W, Zhou Z, Xu LX, Jia W, Zheng S, Yen Y, Jia W.
TitleA distinct metabolic signature of human colorectal cancer with prognostic potential.
JournalClin Cancer Res. 2014 Apr 15;20(8):2136-46.
AbstractPURPOSE: Metabolic phenotyping has provided important biomarker findings, which, unfortunately, are rarely replicated across different sample sets due to the variations from different analytical and clinical protocols used in the studies. To date, very few metabolic hallmarks in a given cancer type have been confirmed and validated by use of a metabolomic approach and other clinical modalities. Here, we report a metabolomics study to identify potential metabolite biomarkers of colorectal cancer with potential theranostic value. EXPERIMENTAL DESIGN: Gas chromatography-time-of-flight mass spectrometry (GC-TOFMS)-based metabolomics was used to analyze 376 surgical specimens, which were collected from four independent cohorts of patients with colorectal cancer at three hospitals located in China and City of Hope Comprehensive Cancer Center in the United States. Differential metabolites were identified and evaluated as potential prognostic markers. A targeted transcriptomic analysis of 29 colorectal cancer and 27 adjacent nontumor tissues was applied to analyze the gene expression levels for key enzymes associated with these shared metabolites. RESULTS: A panel of 15 significantly altered metabolites was identified, which demonstrates the ability to predict the rate of recurrence and survival for patients after surgery and chemotherapy. The targeted transcriptomic analysis suggests that the differential expression of these metabolites is due to robust metabolic adaptations in cancer cells to increased oxidative stress as well as demand for energy, and macromolecular substrates for cell growth and proliferation. CONCLUSIONS: These patients with colorectal cancer, despite their varied genetic background, mutations, pathologic stages, and geographic locations, shared a metabolic signature that is of great prognostic and therapeutic potential.

Sample characteristics

SpeciesTissue / SourceDiseaseNDetection methodSample
Homo sapienscolon_rectumCRC tumor23GC-TOFMSDem24526730c

Sample description and preparation

Disease (case)CRC tumor
Disease (control)non-tumor tissue

Sample analysis

Software thresholdP<0.05

Molecule list

Molecule IDextExternal IDNameSource accRegulation (case/control)Scores
CHEBI5445 5445glyceraldehydeGlyceraldehydedratio: 1.37
CHEBI15428 15428glycineGlycinedratio: 1.53
CHEBI15729 15729L-OrnithineOrnithinedratio: 2.28
CHEBI16610 16610spermidineSpermidineratio: 2.34
CHEBI16668 16668hypotaurineHypotaurineratio: 3.84
CHEBI16865 168654-Aminobutanoic acid4-Aminobutyrateratio: 2.27
CHEBI16946 16946L-KynurenineKynureninedratio: 4.31
CHEBI16958 16958beta-alanine?-Alaninedratio: 6.01
CHEBI17053 17053L-Aspartic acidAspartatedratio: 1.49
CHEBI17148 17148putrescinePutrescinedratio: 4.46
CHEBI17154 17154nicotinamideNicotinamideratio: 1.53
CHEBI17196 17196AsparagineAsparaginedratio: 1.96
CHEBI17268 17268myo-inositolMyo-inositoldratio: -1.66
CHEBI17368 17368hypoxanthineHypoxanthinedratio: 2.12
CHEBI17561 17561L-cysteineCysteinedratio: 1.33
CHEBI17568 17568uracilUracildratio: 2.37
CHEBI17588 17588L-homocysteineHomocysteinedratio: 2.33
CHEBI17754 17754glycerolGlyceroldratio: 1.28
CHEBI18183 181835-Oxo-L-proline5-Oxoprolinedratio: 2.13
CHEBI18237 18237glutamic acidGlutamatedratio: 1.87
CHEBI28716 287169-Hexadecenoic acidPalmitoleatedratio: 2.7
CHEBI28875 28875Tetradecanoic acidMyristatedratio: 2.15
CHEBI78320 783202-Hydroxypropanoic acidLactatedratio: 1.45
CHEBI86508 86508alpha-aminobutyrate2-Aminobutyratedratio: 1.58

Compile date 10-20-2017© .